Rovi stock faces Neparvis expiry as results date nears
Published on 10/17/2026 at 10:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDates and licensing developments
- Rovi's investor-relations calendar schedules first nine months 2026 results for November 5, 2026.
- Distribution of Neparvis in Spain reached its reported license expiry on October 16, 2026.
- Rovi's latest reported Neparvis sales totaled EUR 28.20 million in the first half of 2026.
real-time quote of Rovi stock remains available for the next trading phase.
Market context: Market report IBEX 35.
Upcoming results date
Rovi's investor-relations calendar lists the company's first nine months 2026 financial results for November 5, 2026. The calendar identifies the event as the release of results for the nine-month period ended September 30, 2026.
Neparvis license expiry
El Economista reported on October 17, 2026 that the Spanish distribution license for Neparvis expired on October 16, 2026. The report said Rovi and Novartis were discussing a possible extension.
The report said Neparvis generated EUR 28.20 million in sales from January through June 2026, compared with EUR 27.70 million in the same period of 2025. It also reported EUR 56.70 million in Neparvis sales for 2025.
Next Xetra session
The next Xetra session is scheduled for October 19, 2026. Rovi's next company-marked date is the November 5, 2026 release of its first nine months 2026 results.
